mhurhangee/patent-ind-claim-en huggingface dataset:
A computer-implemented method for providing a real-time estimate of glycosylated hemoglobin (HbA1c) of a patient having Type 1 diabetes from a self-monitoring blood glucose (SMBG) measurement, and tracking changes in average glycemia of said patient over time, the method comprising the steps of: computing a surrogate fasting measurement, based on unstructured SMBG data received from the patient on consecutive days, wherein said unstructured SMBG data is aggregated according to time bins for said consecutive days; computing a glycation value using the said surrogate fasting measurement and a calibration offset in a predetermined glycation equation, wherein said calibration offset is calculated according to components of a blood glucose (BG) profile computed from values of said aggregated unstructured SMBG data, such that said BG profile defines a surrogate for a seven-point SMBG profile for said patient; outputting said glycation value as an initial estimate of HbA1c upon initialization of tracking of said patient's average glycemia; updating said glycation value by using an updated SMBG value in said predetermined glycation equation, said updated SMBG value being based on a subsequent computed surrogate fasting measurement; computing an updated estimate of HbA1c using said initial estimate of HbA1c and said updated glycation value in a predetermined HbA1c estimation equation; and outputting said updated estimate of HbA1c to a user. computing a surrogate fasting measurement, based on unstructured SMBG data received from the patient on consecutive days, wherein said unstructured SMBG data is aggregated according to time bins for said consecutive days; computing a glycation value using the said surrogate fasting measurement and a calibration offset in a predetermined glycation equation, wherein said calibration offset is calculated according to components of a blood glucose (BG) profile computed from values of said aggregated unstructured SMBG data, such that said BG profile defines a surrogate for a seven-point SMBG profile for said patient; outputting said glycation value as an initial estimate of HbA1c upon initialization of tracking of said patient's average glycemia; updating said glycation value by using an updated SMBG value in said predetermined glycation equation, said updated SMBG value being based on a subsequent computed surrogate fasting measurement; computing an updated estimate of HbA1c using said initial estimate of HbA1c and said updated glycation value in a predetermined HbA1c estimation equation; and outputting said updated estimate of HbA1c to a user.
In an integrated circuit, an active shield for detecting an intrusion on the integrated circuit, the active shield comprising: a first driver to drive a first conductive track having a first predetermined routing within the integrated circuit; and a second driver to drive a second conductive track having a second predetermined routing within the integrated circuit; wherein at least a part of the second conductive track lies adjacent to a part of the first conductive track at a given spacing and over a given length of the two conductive tracks, the given spacing and the given length being such that a rising or falling edge of a pulse generated on the second conductive track causes a glitch to appear on the first conductive track due to a resulting mutual capacitance between the first and second conductive tracks; characterised in that the active shield is configured to: drive a first number of test pulses on the second conductive track during a detection phase; and detect for glitches on the first conductive track during the detection phase and to compare a number of detected glitches with a number of expected pulses, the number of expected pulses being related to but not exceeding the first number of test pulses. a first driver to drive a first conductive track having a first predetermined routing within the integrated circuit; and a second driver to drive a second conductive track having a second predetermined routing within the integrated circuit; drive a first number of test pulses on the second conductive track during a detection phase; and detect for glitches on the first conductive track during the detection phase and to compare a number of detected glitches with a number of expected pulses, the number of expected pulses being related to but not exceeding the first number of test pulses.
An injector device for delivering a liquid medicament, comprising: - an injector body having a proximal end and a distal end , - a syringe slidably received in the injector body and moveable from a first position to a second position towards the distal end of the body , - a needle holder between the syringe and the distal end of the body , - a needle held in the needle holder and including a distal end extending toward an opening in the distal end of the body , and a proximal end extending toward the syringe , and - a syringe biasing member within the body configured to bias the syringe into the second position, - wherein the syringe is spaced from the needle in the first position and is in engagement with the proximal end of the needle in the second position, wherein the needle holder is slidably mounted in the body and moveable from a retracted position to an extended position toward the distal end of the body , and wherein the injector device further comprises a needle holder biasing member provided between the needle holder and the distal end of the syringe , characterized in that the needle holder biasing member is in contact with the needle holder and syringe in the first position of the device to bias the needle holder away from the syringe , and is configured to bias the needle holder into the extended position. - an injector body having a proximal end and a distal end , - a syringe slidably received in the injector body and moveable from a first position to a second position towards the distal end of the body , - a needle holder between the syringe and the distal end of the body , - a needle held in the needle holder and including a distal end extending toward an opening in the distal end of the body , and a proximal end extending toward the syringe , and - a syringe biasing member within the body configured to bias the syringe into the second position, - wherein the syringe is spaced from the needle in the first position and is in engagement with the proximal end of the needle in the second position, wherein the needle holder is slidably mounted in the body and moveable from a retracted position to an extended position toward the distal end of the body , and
A ureteral stent , comprising: a solid wire , having one or more retention mechanisms at a distal end ; a delivery catheter capable of maintaining the one or more retention mechanisms in a delivery configuration; wherein the one or more retention mechanisms are configured to expand to a flared end at times the delivery catheter is removed. a solid wire , having one or more retention mechanisms at a distal end ; a delivery catheter capable of maintaining the one or more retention mechanisms in a delivery configuration; wherein the one or more retention mechanisms are configured to expand to a flared end at times the delivery catheter is removed.
A structure comprising, on a semiconductor support , a portion of a semiconductor layer, or of a stack of semiconductor layers, comprising germanium, and a silicon nitride layer surrounding and straining the portion , wherein the semiconductor support is separated from the silicon nitride layer by a metal foot .
Method for producing a measurement transducer for a sensor device , which has a magnetic body as the measurement transducer , the magnetic field orientation of which can be detected by at least one measurement value sensor, so that the current position of the measurement transducer can be deduced depending on the detected magnetic field orientation, having the following steps: - providing a magnetic body , - providing a coil which can be supplied with a current, - forming the coil into a helical winding, whose inner diameter is greater than the outer contour of the magnetic body , wherein - the winding is formed in such a way that its gradient - viewed in the longitudinal extension of the winding - changes at least in some sections, - arranging the magnetic body within the coil , in particular, coaxially to each other, - supplying current to the coil to magnetize the magnetic body for producing the measurement transducer , so that the magnetization of the magnetic body or its magnetic field orientation also extends in a helical or screw-shaped pattern, according to the helical path of the coil , along the magnetic body , and - removing the coil . - providing a magnetic body , - providing a coil which can be supplied with a current, - forming the coil into a helical winding, whose inner diameter is greater than the outer contour of the magnetic body , wherein - the winding is formed in such a way that its gradient - viewed in the longitudinal extension of the winding - changes at least in some sections, - arranging the magnetic body within the coil , in particular, coaxially to each other, - supplying current to the coil to magnetize the magnetic body for producing the measurement transducer , so that the magnetization of the magnetic body or its magnetic field orientation also extends in a helical or screw-shaped pattern, according to the helical path of the coil , along the magnetic body , and - removing the coil .
A method of enabling data exchange between a first communication network having first data communication capabilities and a second communication network having second data communication capabilities different from said first data communication capabilities, said first and second data communication capabilities at least comprising different Quality of Service, QoS, and data transmission attributes, said method comprising: - mapping , in a network function (7-14; 60) of said first communication network , communication attributes of corresponding first and second data communication capabilities, including said QoS and data transmission attributes; - allocating , by said network function (7-14; 60) of said first communication network , based on said attributes mapping and communication resources available in said first communication network , first data communication capabilities of said first communication network for use by said second communication network , and - advertising , by said network function (7-14; 60) of said first communication network , said allocated data communication capabilities to said second communication network , represented in accordance with said second data communication capabilities based on said attributes mapping characterised in that said allocating is based on communication resources available in said first communication network excluding communication resources prohibited from being allocated for said second communication network. - mapping , in a network function (7-14; 60) of said first communication network , communication attributes of corresponding first and second data communication capabilities, including said QoS and data transmission attributes; - allocating , by said network function (7-14; 60) of said first communication network , based on said attributes mapping and communication resources available in said first communication network , first data communication capabilities of said first communication network for use by said second communication network , and - advertising , by said network function (7-14; 60) of said first communication network , said allocated data communication capabilities to said second communication network , represented in accordance with said second data communication capabilities based on said attributes mapping
A photocurable resin composition that can be used for an image display device composed of an image display member and a light-transmitting cover member that are laminated via a light-transmitting photocured resin layer formed from the photocurable resin composition, the photocurable resin composition comprising the following components (A) to (D): <Component (A)> a (meth)acrylate polymer with a hydroxyl value of 120 mgKOH/g or more and having no (meth)acryloyl group; <Component (B)> a hydroxyl group-containing monofunctional (meth)acrylate monomer; <Component (C)> a hydroxyl group-free monofunctional (meth)acrylate monomer; and <Component (D)> a hydrogen abstraction-type photopolymerization initiator, wherein the photocurable resin composition has a viscosity of 10 mPa·s or more at 25°C and 30 mPa·s or less at 60°C, determined as described in the specification. <Component (A)> a (meth)acrylate polymer with a hydroxyl value of 120 mgKOH/g or more and having no (meth)acryloyl group; <Component (B)> a hydroxyl group-containing monofunctional (meth)acrylate monomer; <Component (C)> a hydroxyl group-free monofunctional (meth)acrylate monomer; and <Component (D)> a hydrogen abstraction-type photopolymerization initiator, wherein the photocurable resin composition has a viscosity of 10 mPa·s or more at 25°C and 30 mPa·s or less at 60°C, determined as described in the specification. a hydrogen abstraction-type photopolymerization initiator, wherein the photocurable resin composition has a viscosity of 10 mPa·s or more at 25°C and 30 mPa·s or less at 60°C, determined as described in the specification.
A method for identifying a cancer likely to respond to Compound A, consisting of 5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(1H-indol-2-yl)-methanone, comprising (a) determining the levels of expression of FGFR1, FGFR2 and FGFR3 in a tumor or liquid biopsy from a subject suffering from a cancer, and (b) if the determined level of expression of at least one of FGFR1, FGFR2 and FGFR3 exceeds a pre-established threshold level, determining that the subject has a cancer likely to respond to an effective amount of Compound A, wherein levels of expression of FGFR1, FGFR2 and FGFR3 are measured at the messenger RNA level, and wherein the pre-established threshold level of expression of at least one FGFR corresponds to any level from the 44% to the 73% cutoff level of expression for the at least one FGFR, corresponding to expression levels relative to the median of levels of mRNA expression of a set of 16 reference genes measured by the nCounter Gene Expression Assay from 0.104 to 0.641 for FGFR1, from 0.257 to 1.094 for FGFR2, and from 0.128 to 0.815 for FGFR3, the 16 reference genes being ACTB, ALAS1, CLTC, MRPL19, RPL19, RPLPO, SF3A1, TBP, TUBB, c1orf43 exon 1, c1orf43 exon 2, CHMP2A exon 3, EMC7 exon 5, EMC7 exon 3, GPI exon 4 and GPI exon 6. (a) determining the levels of expression of FGFR1, FGFR2 and FGFR3 in a tumor or liquid biopsy from a subject suffering from a cancer, and (b) if the determined level of expression of at least one of FGFR1, FGFR2 and FGFR3 exceeds a pre-established threshold level, determining that the subject has a cancer likely to respond to an effective amount of Compound A,
A method for monitoring the safe operation of potential runaway reactions performed in a non-continuous indirectly cooled semibatch reactor (SBR), comprising the steps of: - providing at least one reactant (B) in said reactor; - feeding at least one coreactant (A); - measuring process variables, wherein said process variables comprise at least the temperature (T2) of the reaction mass, the temperature (T1) of the feed stream, the inlet and outlet temperatures (T3, T4) of a coolant of said reactor, the flowrate (F1) of said coreactant (A), and the flowrate (F2) of said at least one coolant; - calculating an integral parameter (X) of the conversion degree of said coreactant (A) on the basis of said measured process variables, said integral parameter (X) being the ratio between the reacted coreactant and the fed coreactant, wherein the reacted coreactant is expressed in terms of energy uses as a function of the enthalpy of the reaction mass and of the coolant, and wherein the fed coreactant is expressed in terms of overall energy sources as a function of the reaction enthalpy; and - checking if said integral parameter (X) is within a predetermined target range, wherein said integral parameter (X) is equal to: X = m C ^ P 0 T − T 0 + m C ^ P fed T − T dos + ∫ 0 t m ̇ C ^ P ΔT cool dt − Δ H ^ r m fed ω A / ν A × 100 where m indicates the mass, ṁ indicates the mass flowrate, Ĉ p is the mass heat capacity at constant pressure, T is the reactor temperature, ΔT is the coolant temperature variation, ΔH is the reaction enthalpy, ω A is the mass fraction of said coreactant (A), ν A is the stochiometric coefficient of said coreactant (A), O refers to the beginning of the feeding of said coreactant (A), T o is the reactor temperature at the beginning of the supply period, cool refers to the coolant of said reactor, and dos refers to the dosed coreactant. - providing at least one reactant (B) in said reactor; - feeding at least one coreactant (A); - measuring process variables, wherein said process variables comprise at least the temperature (T2) of the reaction mass, the temperature (T1) of the feed stream, the inlet and outlet temperatures (T3, T4) of a coolant of said reactor, the flowrate (F1) of said coreactant (A), and the flowrate (F2) of said at least one coolant; - calculating an integral parameter (X) of the conversion degree of said coreactant (A) on the basis of said measured process variables, said integral parameter (X) being the ratio between the reacted coreactant and the fed coreactant, wherein the reacted coreactant is expressed in terms of energy uses as a function of the enthalpy of the reaction mass and of the coolant, and wherein the fed coreactant is expressed in terms of overall energy sources as a function of the reaction enthalpy; and - checking if said integral parameter (X) is within a predetermined target range,
An acetabular implant system , comprising: an acetabular shell including an inner surface and a lip portion defining an opening; a liner having an edge portion ; and a fitting ring , having an alignment portion for correcting any pivoting of the liner relative to the acetabular shell and an engagement portion engageable to the edge portion of the liner such that the alignment portion extends radially outward from the liner ; wherein the alignment portion is on an exterior surface of the fitting ring , the alignment portion extending circumferentially around the fitting ring ; wherein the engagement portion is on an interior surface of the fitting ring and defines an opening for receiving the liner , wherein the alignment portion is engageable to the circumference of the lip portion of the acetabular shell to position the liner within the opening at a predetermined distance from the inner surface of the acetabular shell; and wherein the engagement portion comprises an annular snap fit feature positioned on the interior surface of the fitting ring . an acetabular shell including an inner surface and a lip portion defining an opening; a liner having an edge portion ; and a fitting ring , having an alignment portion for correcting any pivoting of the liner relative to the acetabular shell and an engagement portion engageable to the edge portion of the liner such that the alignment portion extends radially outward from the liner ; wherein the alignment portion is on an exterior surface of the fitting ring , the alignment portion extending circumferentially around the fitting ring ; wherein the engagement portion is on an interior surface of the fitting ring and defines an opening for receiving the liner , wherein the alignment portion is engageable to the circumference of the lip portion of the acetabular shell to position the liner within the opening at a predetermined distance from the inner surface of the acetabular shell; and the engagement portion is on an interior surface of the fitting ring and defines an opening for receiving the liner , wherein the alignment portion is engageable to the circumference of the lip portion of the acetabular shell to position the liner within the opening at a predetermined distance from the inner surface of the acetabular shell; and wherein the engagement portion comprises an annular snap fit feature positioned on the interior surface of the fitting ring .
A detergent comprising: a surfactant (a) having a critical micelle concentration (CMC) of 0.10 g/L or lower, represented by the formula : R 1 -[-O-(A 1 O) n -H] m wherein R 1 is a C7-C20 hydrocarbon group having a valence number of m; m is an integer of 2 to 6; A 1 in (A 1 O) n in each of [-O-(A 1 O) n -H] m is each independently C2-C4 alkylene group, wherein within a given surfactant of the formula , a mixture of A 1 groups is present within that formula (I), such that an ethylene group is present as an A 1 group in combination with at least one further A 1 group selected from the group consisting of a 1,2-propylene group, a 1,2-butylene group, a 1,3-butylene group and a 2,3-butylene group; n in [-O-(A 1 O) n -H] m is each independently an integer of 1 to 100; and the sum of n in [-O-(A 1 O) n -H] m is 30 to 70; and a surfactant (b) represented by the formula : R 2 -X-(A 2 O) p -H wherein R 2 is a C10-C18 monovalent hydrocarbon group; X is -COO- or -O-; A 2 is each independently a C2-C4 alkylene group; and p is an integer of 1 to 30. a surfactant (a) having a critical micelle concentration (CMC) of 0.10 g/L or lower, represented by the formula : R 1 -[-O-(A 1 O) n -H] m wherein R 1 is a C7-C20 hydrocarbon group having a valence number of m; m is an integer of 2 to 6; A 1 in (A 1 O) n in each of [-O-(A 1 O) n -H] m is each independently C2-C4 alkylene group, wherein within a given surfactant of the formula , a mixture of A 1 groups is present within that formula (I), such that an ethylene group is present as an A 1 group in combination with at least one further A 1 group selected from the group consisting of a 1,2-propylene group, a 1,2-butylene group, a 1,3-butylene group and a 2,3-butylene group; n in [-O-(A 1 O) n -H] m is each independently an integer of 1 to 100; and the sum of n in [-O-(A 1 O) n -H] m is 30 to 70; and a surfactant (b) represented by the formula : R 2 -X-(A 2 O) p -H wherein R 2 is a C10-C18 monovalent hydrocarbon group; X is -COO- or -O-; A 2 is each independently a C2-C4 alkylene group; and p is an integer of 1 to 30.